Fig. 5: Nigericin decreases OCR in an active caspase-1-dependent manner.

a, Percentage LDH release from BMDMs treated with LPS (100 ng ml^–1) and Nigericin (20 μM), with or without VX-765 (20 μg ml^–1) (n = 10 UT, LPS, LPS + 60 min nigericin; n = 8 LPS + 10 min nigericin, LPS + 20 min nigericin, LPS + 30 min + nigericin; n = 6 LPS + 5 min nigericin, LPS + 60 min nigericin + VX-765; n = 4 LPS + 120 min nigericin, LPS + 120 min nigericin + VX-765). b, OCR of BMDMs treated for 6 h with LPS in the presence or absence of VX-765 (20 µg ml^–1). Nigericin was added (final concentration 20 μM) at indicated time (n = 2; error bars s.d. of four technical replicates). c, ECAR of BMDMs treated as in b (n = 2; error bars represent s.d. of four technical replicates). d, OCR of BMDMs treated for 6 h with LPS (100 ng ml^–1), with or without VX-765 (20 µg ml^–1). Nigericin (final concentration 20 μM), Oligomycin (final concentration 2 μM), and 2DG (final concentration 50 mM) were added at indicated timepoints (n = 2, representative of eight mice in four independent experiments). e, ECAR of BMDMs treated as in d (n = 2, representative of eight mice in four independent experiments). f, OCR of BMDMs treated for 6 h with LPS (100 ng ml^–1) and VX-765 (20 μg ml^–1) with or without piericidin A (500 nM) (n = 2, representative of eight mice in four independent experiments). g, ECAR of BMDMs treated as in f (n = 2, representative of eight mice in four independent experiments). Data are means ± s.e.m. (a) or s.d. (b–g). *P < 0.0001, one-way ANOVA with Turkey’s post hoc test for multiple comparisons.